FRPath.org
Where the Roads to Accelerated Assessments Converge

FRPath.org Country and FRP Information Input Form		
Country: Taiwan (Chinese Taipei)	**Agency Name:** Taiwan Food and Drug Administration (TFDA)	
Name of FRP: Priority Review		
Is this FRP Proposed or Active? Active		
Date FRP was officially enacted: Click here to enter a date.		
1. Facilitates activities during development	**2. Accelerates the regulatory review process**	**3. Relies on or recognizes a prior regulatory decision**
☐	☒	☒
Is a Guidance or SOP describing how to apply this FRP publicly available?	Yes- see reference below	
When should the FRP be requested?	At the time of the submission	
Does the agency provide assistance/advice to the sponsor?	Yes- For any product type	
For which types of product(s) can this FRP be used? E.g. NMEs, generics, biologics, biosimilars, all products	Priority Review (meet two of the following criteria): 1. New chemical entities, new combination, new indication and new administration route. 2. An application for a drug which addresses unmet medical need in the treatment of serious conditions and, if approved, would provide major clinical advance. 3. An application for a drug which addresses unmet medical need and is under special national scientific research and development programs.	
Must the product address an unmet medical need or serious condition?	Yes	
If a fee is required, what is the amount (in US$ equivalent)	Click here to enter text.	
Total target (agency) time for assessment (calendar days)	Priority Review: 240days Submission → filing meeting (~40 days) → review meeting (~100 days) → notification for completion of review (~130 days) → advisory committee (130~210 days) → approval/non-approval by TFDA (~240 days).	
Total target (company) time for responses to agency questions (If stated)	Click here to enter text.	
Select one of the following (* see definitions at end of document)		
Is this a verification review (a recognition pathway)?*	**Is this an abridged* review (selected dossier portions)? (a reliance pathway)?***	**Is this a full* review of all parts of the dossier?**

FRPath.org Country and FRP Information Input Form		
☐	☒	☐
If this is a reliance or recognition pathway, what are the accepted reference agencies?	Click here to enter text.	
How many reference agency decisions are required?	Click here to enter text.	
Does this FRP require submission of Assessment Reports from prior decisions?	Unredacted	
Is a CPP (Certificate of Pharmaceutical Product) required for approval?	Yes at time of submission	
Can an alternate form of reference documentation to the CPP be used? If so, what types of documents?	The Free Sales Certificate (FSC) from the country of origin and the CPP are not required for the application of New Chemical Entity (NCE) drugs. In cases where the FSC from the country of origin and CPP are submitted for the application, the central health competent authority may adjust the review process according to the actual situation.	
If this process is through a Regional Regulatory Initiative, which countries participate in this process?	No, this process is not through a Regional Regulatory Initiative.	
Does the product have to have been marketed in another country? For a specific amount of time? If so, for how long?	Yes, the product has to have been marketed in another country.	
How are queries to the companies sent?	Choose an item.	
Are external reviewers (e.g. non-agency) involved in the assessment?	Yes- as needed	
Post-authorization study commitments	Always required	
For how long is the initial approval or designation valid?	Choose an item.	
Any other details you wish to provide?	- Applications which are not prepared in CTD format or without complete administrative or technique documents are subject to Refusal to File (RTF) decisions. - Drug products that are for priority review have the following criteria: 1. Accelerating approval for drugs for serious conditions	

FRPath.org Country and FRP Information Input Form	
	that fill an unmet medical need 2. Base on a surrogate endpoint: A laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit 3. Studies that demonstrate a drug's effect on a surrogate endpoint must be "adequate and well controlled". 4. Post-marketing (Phase IV) confirmatory trials are generally required to verify clinical efficacy (REMS/RPMs could be required). - Applicants of New Chemical Entity (NCE) drugs should submit a CPP issued by any one of the A10 countries, plus the dossiers of clinical trials to clinically and statistically justify drug safety and effectiveness in the population in Chinese Taipei. If necessary, the central health competent authority may request the submission of a Post-Approval Risk Management Plan. According to the "Regulations for Registration of Medicinal Products", Article 7, A10 countries include Germany, US, UK, France, Japan, Switzerland, Canada, Australia, Belgium, and Sweden or the CPP issued by the EMA (European Medicine's Agency).
Date of this update	14 JANUARY 2020
References	1. Regulations for Registration of Medicinal Products. https://www.fda.gov.tw/ENG/lawContent.aspx?cid=5060&id=3144 Accessed on 6 January 2020 2. Fee-Charging Standards for the Review of Medicament and Cosmetic Advertisements. Accessed on 6 January 2020. 3. Taiwan Drug Approval Process. https://www.fda.gov.tw/eng/newsContent.aspx?id=22247 Accessed on 6 January 2020.

*Definitions:

Verification review: A checklist review based on recognition of a prior regulatory decision. Recognition is the routine acceptance of the regulatory decision of another regulator or other trusted institution. Recognition indicates that evidence of conformity with the regulatory requirements of economy A is sufficient to meet the regulatory requirements of economy B.

Abridged review: An abbreviated review of selected portions of the dossier and the reliance on prior assessment decisions. Reliance is the act whereby a regulatory authority in one jurisdiction may take into account/give significant weight to work performed by another regulator or other trusted institution in reaching its own decision

Full review: A comprehensive review of all components of the dossier. This may or may not be CPP-dependent. This may form part of a reliance or recognition pathway.